EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence

Jian-Yu Jhu, Yu-Wei Fang, Chung-Yen Huang, Hung-Hsiang Liou, Mon-Ting Chen, Ming-Hsien Tsai iD

Journal of Diabetes Investigation · 2025

DOI: 10.1111/jdi.14361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Jian-Yu Jhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Diabetic Nephropathies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shin Kong Wu Ho-Su Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Developing a more effective treatment for the global impact of diabetic kidney disease is crucial. This study examined the renoprotective effects of combining glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) with sodium–glucose cotransporter 2 inhibitors (SGLT2i) compared to SGLT2is alone in type 2 diabetes (DM). Materials and Methods This retrospective cohort study used data from the TriNetX Global Collaborative Network. Type 2 DM patients with estimated glomerular filtration rates ≥60 mL/min/1.73 m 2 who used GLP‐1 RA or SGLT2i between January 1, 2013, and December 31, 2023. Propensity score matching balanced baseline characteristics, resulting in 71,186 patients in each group (combined GLP‐1 RA and SGLT2i therapy vs SGLT2i alone). Cox regression model was adopted to compare outcomes over a 5‐year period, including major adverse kidney events (MAKE), acute kidney injury (AKI), end‐stage kidney disease (ESKD), and all‐cause mortality.

Results

After matching, the average age was 57.1 ± 10.8 years for the GLP‐1 RA plus SGLT2i group and 57.2 ± 11.7 years for the SGLT2i‐only group. The GLP‐1 RA plus SGLT2i group had significantly lower risk of MAKE (hazard ratio [HR]: 0.73, 95% confidence interval [CI]: 0.69–0.77), AKI (HR: 0.82, 95% C0I: 0.77–0.87), ESKD (HR: 0.61, 95% CI: 0.47–0.78), and all‐cause mortality (HR: 0.54, 95% CI: 0.50–0.58) compared to the SGLT2i‐only group. Moreover, subgroup analyses showed consistent benefits across different subgroups.

Conclusions

Dual therapy with GLP‐1 RA and SGLT2i is supported to enhance renal outcomes and address the growing burden of diabetic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsDiabetic NephropathiesHypoglycemic AgentsHumansMaleMiddle AgedFemaleRetrospective StudiesAgedDrug Therapy, CombinationGlomerular Filtration RateFollow-Up StudiesAcute Kidney InjuryPrognosis

Stichwörter der Autor:innen

Glucagon‐like peptide‐1 receptor agonistsMajor adverse kidney eventsSodium–glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • Department of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
  • Department of Health Care Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Hsin-Jen Hospital, New Taipei City, Taiwan.

ORCID-Profile: Ming-Hsien Tsai

Förderung

  • Shin Kong Wu Ho-Su Memorial Hospital

Zitieren

APA

Jhu, J. Y., Fang, Y. W., Huang, C. Y., Liou, H. H., Chen, M. T., & Tsai, M. H. (2025). Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14361

Vancouver

Jhu JY, Fang YW, Huang CY, Liou HH, Chen MT, Tsai MH. Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14361

BibTeX
@article{Jhu2025,
  author = {Jhu, Jian-Yu and Fang, Yu-Wei and Huang, Chung-Yen and Liou, Hung-Hsiang and Chen, Mon-Ting and Tsai, Ming-Hsien},
  title = {Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence},
  journal = {Journal of Diabetes Investigation},
  year = {2025},
  doi = {10.1111/jdi.14361}
}
Kostenlos starten →